BI 473494

Drug Profile

BI 473494

Alternative Names: BI-473494

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim
  • Class Obesity therapies
  • Mechanism of Action Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 06 Nov 2017 Boehringer Ingelheim suspends patient enrolment in a phase I trial due to risk-benefit profile being re-evaluated for an unknown indication (In volunteers) in Germany (SC) (NCT03195088)
  • 27 Jul 2017 Phase-I clinical trials in Obesity (In volunteers) in Germany (SC) (NCT03195088)
  • 20 Jun 2017 Boehringer Ingelheim plans a phase I trial for an unknown indication (In volunteers) in Germany (SC) (NCT03195088)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top